Esperion Therapeutics, Inc. - ESPR STOCK NEWS

Esperion (NASDAQ: ESPR) granted stock options and restricted stock units (RSUs) to four new employees on January 27, 2022. Notably, Benjamin Looker, the new General Counsel, received options to purchase 100,450 shares at an exercise price of $3.65 per share and 70,800 RSUs. The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly. This granting aligns with the 2017 Inducement Equity Incentive Plan, aimed at attracting new talent to the company, which focuses on innovative cholesterol-lowering therapies.

Esperion (NASDAQ: ESPR) announced preliminary Q4 2021 net U.S. product revenue estimated between $12.0 and $12.5 million. The company maintains its full-year 2022 operating expense guidance at $220 million to $240 million, inclusive of $25 million in non-cash stock-compensation expenses. A significant milestone is the ongoing CLEAR Outcomes Trial, achieving 85% major adverse cardiac events (MACE) accumulation by December 2021. The company will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022.

Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 10:30 a.m. ET. The presentation will include a live audio webcast available on the company's investor relations website, with replays archived for 90 days. Esperion focuses on lipid management, developing innovative medicines to lower cholesterol for patients underserved by existing solutions. More details can be found at www.esperion.com.

Esperion has appointed Benjamin O. Looker as general counsel effective January 1, 2022. Looker brings extensive experience from his previous roles in the pharmaceutical industry, including serving as general counsel at Trillium Therapeutics. His expertise will be critical as Esperion approaches significant milestones, particularly the completion of the CLEAR Outcomes trial and the development of its early-stage pipeline. The leadership believes Looker's guidance will enhance the company's legal, compliance, and ethics operations.

Esperion (NASDAQ: ESPR) has successfully closed its public offering of 32,142,858 shares of common stock and warrants, raising approximately $225 million in gross proceeds. After expenses, net proceeds total around $208.8 million. The underwriter has also partially exercised a 30-day option for additional warrants. The funds will support the commercialization of NEXLETOL and NEXLIZET, as well as research and development efforts. The offering was conducted under a previously filed shelf registration statement with the SEC.

Esperion (NASDAQ: ESPR) has announced a public offering of 32,142,858 shares of common stock, alongside short-term warrants for the same amount, priced at $7.00 each. The offering, set to close on or around December 7, 2021, is expected to generate approximately $225 million in gross proceeds. These funds will be used for commercialization of NEXLETOL and NEXLIZET, pipeline development, and general corporate purposes. The underwriter, H.C. Wainwright & Co., has a 30-day option to purchase an additional 4,821,428 shares or warrants.

Esperion (NASDAQ: ESPR) announced its plan to conduct an underwritten public offering of common stock and warrants, subject to market conditions. The company aims to use the net proceeds for the commercialization of NEXLETOL and NEXLIZET, along with research and development for its pipeline. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering. The offering is subject to various conditions, with no guarantee on its completion or terms. A registration statement has been filed with the SEC, and additional details will be available in a related prospectus.

Esperion announced significant findings from three abstracts on NEXLETOL (bempedoic acid) presented at the AHA Scientific Sessions 2021. Data from pooled Phase 3 studies showed that NEXLETOL effectively lowers LDL-C levels, achieving a ≥30% reduction comparable to high-intensity statins in nearly 1 in 3 patients. In individuals with metabolic syndrome, the treatment resulted in reductions in HbA1c and fasting plasma glucose. Notably, over 50% of patients not on background statins achieved significant LDL-C lowering. This establishes NEXLETOL's role in lipid management.

Esperion (NASDAQ: ESPR) announced a strategic plan to optimize its operational and expense structure, aiming for long-term growth in its lipid management products, NEXLETOL and NEXLIZET. For Q3 2021, U.S. net product revenue reached $10.9 million, driven by a 10% increase in prescriptions, with over 59,200 patients treated. The company reported total revenues of $14.4 million for the quarter, a significant rise from $3.8 million in Q3 2020. Research and development expenses decreased to $25.3 million, while net losses were $69.4 million. Looking ahead, the CLEAR Outcomes study remains on track for completion in 2H 2022.